drugset / Trial / NCT00651846

Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women

NCT00651846

Phase 4 Completed 43 enrolled Bayer
RandomizedCrossoverQuadruple-blindTreatment

Summary

The objective of this study was to investigate the impact of the oral contraceptive YASMIN (containing: drospirenone 3 mg/ethinyl estradiol 30 mcg) in comparison with the oral contraceptive MICROGYNON (containing: levonorgestrel 150 mcg/ethinyl estradiol 30mcg) on factors of blood coagulation and fibrinolysis in female subjects

Timeline

Start
2003-06
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levonorgestrel Small molecule 0.15 mg Oral
Subject drospirenone Unknown 3 mg Oral
Background ethinyl estradiol Small molecule 0.03 mg Oral

Indications

No indication recorded.